Background Numerous studies have proved the advantageous aftereffect of the use of inhibitor of interleukin-1 in the therapy of patients with OA.

Objectives The aim of the study was to estimate the aftereffect of inhibitor of interleukin-1 in therapy of patients with secondary osteoarthritis of the knee in rheumatoid arthritis.

Methods The trial embraced 80 patients with secondary OA of the knee in RA. Their average age was 55,2±11,4, disease lasted from 5 to 15 years. Patients of group 1 (n=40) underwent a 6-month therapy of inhibitor of interleukin-1 (50 mg twice per day) on the basis of methotrexate (10-15 mg per week). 40 patients from group 2 took only methotrexate. RA was diagnosed on the basis of the EULAR/ACR criteria. 12 months later we analyzed the dynamic of clinical parameters: pain on VAS, indexes WOMAC, Lequesne and HAQ. The activity of the underlying disease (RA) was determined traditionally, on the basis of DAS 28. During the period of observation all the patients were getting basic therapy.

Results The activity of RA on DAS 28 statistically significant reduced to 2,56±0,98 (p<0,01) vs 3,47±1,1 before the treatment in group 1, and to 3,23±0,96 (p<0,05) vs 3,9±1,2 in group 2. The level of indexes pain on VAS, WOMAC and Lequesne in group 1 statistically significant decreased to 41±1,51 (p<0,001), 89,9±1,49 (p<0,001) and 9,75±0,28 (p<0,001). Index HAQ in group 1 achieved the average of 0,78±0,31 (p<0,05). Group 1 statistically significant showed better results in comparison with the results in group 2 regarding clinical parameters (pain on VAS, indexes Lequesne, WOMAC) (p<0,05). Despite the advantages in the dynamic of DAS 28 and HAQ in group 1, the comparison of the results in two groups was not statistically significant.

Conclusions As a result the six-month course of complex therapy of secondary osteoarthritis of the knee in patients with rheumatoid arthritis with the use of interleukin-1 inhibitor has its aftereffect. The aftereffect after the new therapeutical approach with the use of the inhibitor of interleukin-1 has shown more advantages if compared to the traditional basis therapy.

Disclosure of Interest : None declared

DOI 10.1136/annrheumdis-2014-eular.3816